Shoring Up Osteoporosis Management: A Fresh Start?
Where this comes from
- Record sourced from PubMed, PMID 39142871.
- Also identified by DOI 10.3122/jabfm.2024.240060R0.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anabolic bone agents, such as parathyroid hormone receptor agonists (teriparatide and abaloparatide) and sclerostin-inhibiting monoclonal antibody (romosozumab), are superior at preventing clinically significant fractures and/or vertebral fractures in women with and without severe osteoporosis compared with bisphosphonates.
Medical subject headings
- Bone Density Conservation Agents
- Osteoporosis